EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies

Luigi Francesco Iannone, Marcello Silvestro, Antonio Munafò iD, Marina Romozzi iD, Pierangelo Geppetti, Antonio Russo iD

Headache: The Journal of Head and Face Pain · 2026-07 · 66 (7) · 1628-1643

DOI: 10.1111/head.70114 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 09.06.2026. Verfasst von Luigi Francesco Iannone und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety, and combination strategies of gepants.

Methods

A scoping review was conducted following PRISMA‐ScR recommendations. A comprehensive search of PubMed/MEDLINE and Scopus was performed from database inception to July 2025, with an additional search in January 2026 for real‐world studies. Data were extracted and summarized narratively without quantitative synthesis.

Results

Second‐ and third‐generation gepants, including ubrogepant, rimegepant, atogepant, and zavegepant, overcome the hepatotoxicity and bioavailability limitations of earlier compounds. Pharmacokinetic properties determine their suitability for both acute and preventive use, and their lack of vasoconstrictive activity makes them suitable for patients with cardiovascular comorbidities. Most are metabolized by cytochrome 3A4 and are substrates for efflux transporters, necessitating awareness of drug–drug interactions, although no clinically significant interactions with common migraine preventive medications have been reported. Preclinical and preliminary clinical evidence indicates a low likelihood of gepants inducing medication‐overuse headache. Combination therapy with other migraine treatments is mechanistically plausible and supported by early pharmacokinetic and safety data, though robust clinical trial evidence remains limited.

Conclusion

Gepants represent an effective and well‐tolerated class of CGRP‐targeted therapies with flexible use in acute and preventive migraine management. Their pharmacological properties support individualized treatment strategies and potential combination approaches; however, long‐term safety, optimal positioning, and the efficacy of combination regimens require further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsHumansDrug Therapy, CombinationCalcitonin Gene-Related PeptidePyridinesPyrroles

Stichwörter der Autor:innen

calcitonin gene‐related peptidedrug‐induced liver injurygepantsmigrainepharmacokineticpharmacology

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin Gene-Related PeptideubrogepantPyridinesPyrroles

Autor:innen und Institutionen

  • Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Inter-Departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

ORCID-Profile: Antonio Munafò, Marina Romozzi, Antonio Russo

Zitieren

APA

Iannone, L. F., Silvestro, M., Munafò, A., Romozzi, M., Geppetti, P., & Russo, A. (2026). The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. Headache: The Journal of Head and Face Pain, 66(7), 1628-1643. https://doi.org/10.1111/head.70114

Vancouver

Iannone LF, Silvestro M, Munafò A, Romozzi M, Geppetti P, Russo A. The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. Headache: The Journal of Head and Face Pain. 2026;66(7):1628-1643. doi:10.1111/head.70114

BibTeX
@article{Iannone2026,
  author = {Iannone, Luigi Francesco and Silvestro, Marcello and Munafò, Antonio and Romozzi, Marina and Geppetti, Pierangelo and Russo, Antonio},
  title = {The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {7},
  pages = {1628--1643},
  doi = {10.1111/head.70114}
}
Kostenlos starten →